BRPI0711608B8 - composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada - Google Patents
composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequadaInfo
- Publication number
- BRPI0711608B8 BRPI0711608B8 BRPI0711608A BRPI0711608A BRPI0711608B8 BR PI0711608 B8 BRPI0711608 B8 BR PI0711608B8 BR PI0711608 A BRPI0711608 A BR PI0711608A BR PI0711608 A BRPI0711608 A BR PI0711608A BR PI0711608 B8 BRPI0711608 B8 BR PI0711608B8
- Authority
- BR
- Brazil
- Prior art keywords
- virus
- viral antigen
- composition
- adapting
- protein
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 6
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 230000003612 virological effect Effects 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 235000000346 sugar Nutrition 0.000 abstract 2
- 229940124859 Rotavirus vaccine Drugs 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 150000008163 sugars Chemical group 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN842CH2006 | 2006-05-12 | ||
IN842/CHE/2006 | 2006-05-12 | ||
PCT/IN2007/000190 WO2007132480A2 (en) | 2006-05-12 | 2007-05-11 | A composition useful as a vaccine |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0711608A2 BRPI0711608A2 (pt) | 2012-08-14 |
BRPI0711608B1 BRPI0711608B1 (pt) | 2019-08-20 |
BRPI0711608B8 true BRPI0711608B8 (pt) | 2021-05-25 |
Family
ID=38578478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0711608A BRPI0711608B8 (pt) | 2006-05-12 | 2007-05-11 | composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada |
Country Status (8)
Country | Link |
---|---|
US (1) | US9642907B2 (pt) |
CN (1) | CN101489587B (pt) |
AU (1) | AU2007251122B2 (pt) |
BR (1) | BRPI0711608B8 (pt) |
GB (1) | GB2451216B (pt) |
MX (1) | MX2008014391A (pt) |
WO (1) | WO2007132480A2 (pt) |
ZA (1) | ZA200809622B (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9598676B2 (en) * | 2009-07-13 | 2017-03-21 | Bharat Biotech International Limited | Composition useful as rotavirus vaccine and a method therefor |
EP2661277A2 (en) * | 2011-01-05 | 2013-11-13 | Bharat Biotech International Limited | A combination heptavalent vaccine |
WO2013105105A2 (en) * | 2012-01-13 | 2013-07-18 | Serum Institute Of India Ltd. | Novel viral vaccine compositions and methods for preparing such vaccines |
CN110227152A (zh) * | 2012-04-23 | 2019-09-13 | 巴拉特生物技术国际有限公司 | 轮状病毒疫苗组合物及其制备方法 |
IN2015DN01342A (pt) * | 2012-08-27 | 2015-07-03 | Murdoch Childrens Res Inst | |
US9480739B2 (en) * | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
AR097762A1 (es) * | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
EP3053594A4 (en) * | 2013-10-03 | 2017-05-10 | Nitto Denko Corporation | Dried influenza vaccine preparation and method for producing dried influenza vaccine preparation |
BR112017000515A2 (pt) * | 2014-07-18 | 2017-11-14 | Msd Wellcome Trust Hilleman Laboratories Pvt Ltd | formulação de vacina contra rotavírus termoestável seca por liofilização e processo para preparação da mesma |
TWI745278B (zh) | 2014-10-10 | 2021-11-11 | 以色列商艾畢克生物實驗有限公司 | 發泡性降低之疫苗組合物 |
EP3355916A4 (en) * | 2015-09-30 | 2018-08-29 | Panacea Biotec Limited | Stable live attenuated recombinant dengue vaccine |
GB201608323D0 (en) * | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
MA44557B1 (fr) * | 2016-06-16 | 2021-11-30 | Bharat Biotech Int Ltd | Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer |
GB201614799D0 (en) * | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
US11110163B2 (en) | 2017-02-14 | 2021-09-07 | Inventprise, Llc | Heat stable vaccines |
KR20190111117A (ko) | 2017-02-14 | 2019-10-01 | 인벤트프라이즈 엘엘씨 | 열 안정성 액체 로타바이러스 백신 |
CN108434106B (zh) * | 2017-04-25 | 2021-07-30 | 广州瑞贝斯药业有限公司 | 一种狂犬病疫苗的冻干制剂 |
CN110055225A (zh) * | 2018-01-18 | 2019-07-26 | 北京依生兴业科技有限公司 | 一种提高轮状病毒产量的方法 |
CN113994925B (zh) * | 2021-12-30 | 2022-04-26 | 北京赛尔富森生物科技有限公司 | 一种轮状病毒攻毒动物模型及其建立方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3629399A (en) * | 1967-09-05 | 1971-12-21 | Behringwerke Ag | Stable poliomyelitis vaccines |
SE445466B (sv) | 1977-12-01 | 1986-06-23 | Wellcome Found | Sett att foroka rotavirus in vitro |
DK0493575T3 (da) * | 1990-07-26 | 1999-06-14 | Wistar Inst | Vaccine af reassortant rotavirus |
US5773009A (en) | 1994-04-15 | 1998-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Rotavirus strain G9P11 |
AU3125795A (en) * | 1994-07-11 | 1996-02-09 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Attenuated human rotavirus vaccine |
US5932223A (en) * | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
US6616931B1 (en) * | 1996-09-26 | 2003-09-09 | Merck & Co., Inc. | Rotavirus vaccine formulations |
US6290967B1 (en) | 1996-12-20 | 2001-09-18 | Merck & Co., Inc. | Stabilizers for lyophilized vaccines |
US6210683B1 (en) * | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
FR2791895B1 (fr) * | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
WO2002024876A2 (en) * | 2000-09-25 | 2002-03-28 | Polymun Scientific Immunbiologische Forschung Gmbh | Live influenza vaccine and method of manufacture |
ES2536322T3 (es) | 2003-12-17 | 2015-05-22 | Wyeth Llc | Procedimiento para producir composiciones de VSR estables en almacenamiento |
KR101152012B1 (ko) * | 2004-11-19 | 2012-07-04 | 인터벳 인터내셔널 비.브이. | 돼지 생식기 및 호흡기 증후군 바이러스 균주 및 조성물 |
GB0503337D0 (en) * | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
WO2007035455A2 (en) * | 2005-09-16 | 2007-03-29 | Merial Limited | Stabilizers for freeze-dried vaccines |
WO2007053781A2 (en) * | 2005-11-01 | 2007-05-10 | Novartis Ag | Compositions with antigens adsorbed to calcium phosphate |
-
2007
- 2007-05-11 US US12/227,250 patent/US9642907B2/en active Active
- 2007-05-11 MX MX2008014391A patent/MX2008014391A/es active IP Right Grant
- 2007-05-11 BR BRPI0711608A patent/BRPI0711608B8/pt active IP Right Grant
- 2007-05-11 GB GB0821386A patent/GB2451216B/en active Active
- 2007-05-11 WO PCT/IN2007/000190 patent/WO2007132480A2/en active Application Filing
- 2007-05-11 AU AU2007251122A patent/AU2007251122B2/en active Active
- 2007-05-11 CN CN200780026055.8A patent/CN101489587B/zh active Active
-
2008
- 2008-11-11 ZA ZA200809622A patent/ZA200809622B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2007251122A1 (en) | 2007-11-22 |
GB0821386D0 (en) | 2008-12-31 |
CN101489587B (zh) | 2015-05-27 |
WO2007132480A3 (en) | 2008-03-20 |
BRPI0711608A2 (pt) | 2012-08-14 |
AU2007251122B2 (en) | 2013-01-10 |
MX2008014391A (es) | 2009-03-06 |
GB2451216A (en) | 2009-01-21 |
US20100068227A1 (en) | 2010-03-18 |
CN101489587A (zh) | 2009-07-22 |
WO2007132480B1 (en) | 2008-05-22 |
US9642907B2 (en) | 2017-05-09 |
WO2007132480A2 (en) | 2007-11-22 |
GB2451216B (en) | 2011-05-04 |
BRPI0711608B1 (pt) | 2019-08-20 |
ZA200809622B (en) | 2009-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0711608B8 (pt) | composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada | |
BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
BR112012022669A2 (pt) | composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. | |
BR112015019066A2 (pt) | Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos | |
BRPI0720667A8 (pt) | Métodos de administração de vacina | |
EA200701519A1 (ru) | Живая аттенуированная ротавирусная вакцина для перорального введения | |
BRPI0511776A (pt) | vìrus atenuado de influenza de suìnos, formulação imunogênica, formulação farmacêutica, métodos para imunizar ou induzir uma resposta imune em um porco, para tratar uma infecção por vìrus de influenza de suìnos em um porco, para tratar cáncer em um porco, e para produzir uma formulação imunogênica, célula, linhagem de células de porco, e, ovo embrionado | |
CO6640289A2 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
BRPI0707779B8 (pt) | antígeno isolado, composição de vacina e método para produção de uma proteína antígeno | |
BR112014004860A2 (pt) | composições de anticorpo contra vírus da influenza | |
BRPI0809663B8 (pt) | composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado. | |
MX2016004063A (es) | Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta. | |
DE60110822D1 (de) | Zubereitung zur immunisierung gegen den aids-virus | |
BR112012004806B8 (pt) | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso | |
ATE503769T1 (de) | Antikörper gegen das humane cytomegalie-virus (hcmv) | |
BRPI0707543B8 (pt) | composição de polipeptídeo e uso da mesma | |
BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
MX351380B (es) | Composiciones y metodos de vacuna de tipo ib de virus de diarrea viral de bovino. | |
BR112014002860A2 (pt) | vacinas de pasteurellaceae | |
BR112018068342A2 (pt) | vacina de vírus zika vivo atenuado | |
ME01140B (me) | Virus goveđe virusne dijareje s modifikovanim erns proteinom | |
BR112021021195A2 (pt) | Métodos para tratamento ou prevenção da asma pela administração de um antagonista de il-33 | |
BR112015021341A2 (pt) | anticorpos neutralizantes de flavivírus e métodos de uso dos mesmos | |
NZ618158A (en) | Compositions and methods for administration of vaccines against dengue virus | |
WO2013104995A3 (en) | Compositions and methods for treating viral infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE A PROCURACAO APRESENTADA NAO POSSUI DATA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B65X | Notification of requirement for priority examination of patent application | ||
B65Z | Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117) | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/08/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |